CV340B’s Northeast Regional Advocacy Group is hosting a webinar titled ‘340B in the Northeast’ scheduled for 11:00am- 12:00pm on Tuesday May 25th, 2021. Webinar will include a brief history of the 340B Drug Pricing Program, current threats to the program, a panel of Northeastern providers and a discussion on advocacy. The panel will discuss how…
Yesterday, HRSA Acting Administrator Diana Espinosa sent letters to Eli Lilly, AstraZeneca, Novartis, Novo Nordisk, Sanofi, and United Therapeutics making clear to the manufacturers that their restrictions on access to 340B pricing at contract pharmacies “have resulted in overcharges and are in direct violation of the 340B statute.” As a result, HRSA is requiring the six manufacturers…
On May 4, 2021, 340B safety-net providers and their trade associations filed a brief in the case brought by AstraZeneca Pharmaceuticals LP (AstraZeneca) against the U.S. Department of Health and Human Services (HHS) seeking to invalidate the former HHS General Counsel’s 2020 Advisory Opinion on contract pharmacy arrangements. The brief was filed jointly with the…
Last week, Arkansas passed legislation (HB 1881) intended to address 340B discriminatory pricing practices by third party payers and pharmacy benefit managers (PBMs). The law also addresses drug manufacturers denying access to 340B pricing at contract pharmacies. The bill has been sent to Governor Asa Hutchinson for his signature. The “340B Drug Pricing Nondiscrimination…
On April 22, 2021, the Indiana General Assembly passed a bill (HB 1405) that protects Indiana 340B safety-net providers from discriminatory and predatory practices by pharmacy benefit managers (PBMs). HB 1405 is expected to be signed into law by the governor of Indiana, Eric J. Holcomb, next week and without objection. HB 1405 prohibits a contract between…
By letter dated April 12, drug manufacturer United Therapeutics (UT) announced additional details regarding the second phase of its restrictive contract pharmacy policy. UT initially sent letters to covered entities in November 2020 notifying them that UT would be implementing a new contract pharmacy policy in two phases. Under the first phase, UT stated that it will deny all…
Last week, Gilead issued a statement that it is delaying a change to its Advancing Access® Patient Assistance/Medication Assistance Program (PAP/MAP) until January 1, 2022. Gilead previously announced that, effective Oct. 1, 2021, pharmacies dispensing drugs to clients enrolled in the PAP/MAP would only be reimbursed for “the amount paid for each bottle plus a dispensing fee and an administrative…
On April 6th, 2021, the New York legislature announced that it was delaying a controversial policy that would require the New York Medicaid program to carve out the pharmacy benefit from the state’s Medicaid managed care program and shift payment of drugs covered under that benefit to fee-for-service reimbursement. The two-year delay represents a big…
Below is a press release issued by CV340B highlighting new research showing that 340B hospitals provide more medication access services than non-340B hospitals. The research was performed by the University of Illinois Chicago and funded, in part, by CV340B. *** CV340B PRESS STATEMENT ON MEDICATION ASSISTANCE PROGRAM STUDY (D0942315)CV340B PRESS STATEMENT ON MEDICATION ASSISTANCE PROGRAM…
On March 23, an op-ed written by three prominent community leaders, Ms. Hazel Dukes, Rev Kirsten John Foy, and Rev Dr. Johnnie Green, was published in several outlets, including savenysafetynet.com and empirereportnetwork.com. Their op-ed highlights the severe damage that will be inflicted on vulnerable communities resulting from the impending policy of the New York Department…